Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

被引：15

作者：

Verstovsek, Srdan

Deeg, H. Joachim ^{[3
]}

Odenike, Olatoyosi ^{[4
]}

Zhu, Joy ^{[5
]}

Kantarjian, Hagop ^{[1
]}

Estrov, Zeev

Scott, Bart Lee ^{[2
]}

Thomas, Deborah A.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Fred Hutchinson Canc Res Ctr, Dept Clin Res, Seattle, WA 98104 USA

[3] Univ Washington, Seattle, WA 98195 USA

[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[5] S BIO, Global Clin Dev, Redwood City, CA USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.3082.3082

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1271 / 1271

页数：1

共 50 条

[31] Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone
Zhao, Ailin
Wang, Xin
Hu, Mengshi
Chen, Lijuan
Niu, Ting
BLOOD, 2022, 140 : 2624 - 2625
[32] Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes
Younes, Anas
Fanale, Michelle A.
McLaughlin, Peter
Copeland, Amanda
Zhu, Joy
Faria, Silvania de Castro
BLOOD, 2010, 116 (21) : 1167 - 1167
[33] Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)
Anders Poulsen
Anthony William
Stéphanie Blanchard
Angeline Lee
Harish Nagaraj
Haishan Wang
Eeling Teo
Evelyn Tan
Kee Chuan Goh
Brian Dymock
Journal of Computer-Aided Molecular Design, 2012, 26 : 437 - 450
[34] Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)
Poulsen, Anders
William, Anthony
Blanchard, Stephanie
Lee, Angeline
Nagaraj, Harish
Wang, Haishan
Teo, Eeling
Tan, Evelyn
Goh, Kee Chuan
Dymock, Brian
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2012, 26 (04) : 437 - 450
[35] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
Jae Yoon Jeon
Qiuhong Zhao
Daelynn R. Buelow
Mitch Phelps
Alison R. Walker
Alice S. Mims
Sumithira Vasu
Gregory Behbehani
James Blachly
William Blum
Rebecca B. Klisovic
John C. Byrd
Ramiro Garzon
Sharyn D. Baker
Bhavana Bhatnagar
Investigational New Drugs, 2020, 38 : 340 - 349
[36] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
Jeon, Jae Yoon
Zhao, Qiuhong
Buelow, Daelynn R.
Phelps, Mitch
Walker, Alison R.
Mims, Alice S.
Vasu, Sumithira
Behbehani, Gregory
Blachly, James
Blum, William
Klisovic, Rebecca B.
Byrd, John C.
Garzon, Ramiro
Baker, Sharyn D.
Bhatnagar, Bhavana
INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 340 - 349
[37] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
Vaddi, Kris
Sarlis, Nicholas J.
Gupta, Vikas
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
[38] MOMELOTINIB HYDROCHLORIDE JAK1/JAK2 inhibitor Treatment of myelofibrosis Treatment of pancreatic cancer
Price, S.
George, T.
Pinilla-Ibarz, J.
DRUGS OF THE FUTURE, 2015, 40 (09) : 561 - 568
[39] BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis
Pardanani, Animesh
Roberts, Andrew W.
Seymour, John F.
Burbury, Kate
Verstovsek, Srdan
Kantarjian, Hagop M.
Begna, Kebede
Yoshitsugu, Hiroyuki
Gestone, Toni Ann
Phillips, Penny
Xing, Guan
Peltz, Gerson
Lorenzi, Matthew V.
Alland, Leila
Woolfson, Adrian
Tefferi, Ayalew
BLOOD, 2013, 122 (21)
[40] Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis
Mascarenhas, John
Baer, Maria R.
Kessler, Craig
Hexner, Elizabeth
Tremblay, Douglas
Price, Leah
Sandy, Lonette
Weinberg, Rona
Pahl, Heike
Silverman, Lewis R.
Goldberg, Judith D.
Kosiorek, Heidi
Dueck, Amylou C.
Hoffman, Ronald
LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1343 - 1345

← 1 2 3 4 5 →